A Landmark Achievement in Interventional Cardiology
The Transcatheter Cardiovascular Therapeutics (TCT) conference remains the world’s most prestigious educational meeting specializing in interventional cardiovascular medicine. At the 2025 assembly, the EnoPace Harmony™ System was officially awarded the #1 Medical Innovation title, a distinction reserved for technologies that demonstrate the highest potential to alter the clinical landscape of heart failure treatment.
This award underscores the medical community’s recognition of endovascular neuromodulation as a viable, highly effective alternative for patients who have historically had limited options. The selection committee—comprised of leading cardiologists, clinical researchers, and medical device experts—evaluated the technology based on its clinical data, technical novelty, and its ability to address the global heart failure crisis.
The Innovation: Redefining the Standard of Care
The Harmony™ System’s victory is rooted in its unique approach to treating Heart Failure with Reduced Ejection Fraction (HFrEF). While traditional pacemakers and ICDs focus on rhythm management, Harmony™ addresses the underlying autonomic imbalance that drives heart failure progression.
Key technical advantages recognized by the TCT panel include:
- Percutaneous Delivery: The ability to implant a sophisticated neurostimulation system via a standard catheter-based procedure, eliminating the need for invasive surgery and reducing perioperative risks.
- Targeted Autonomic Modulation: The system specifically targets the neural pathways responsible for heart rate regulation, allowing for a reduction in left-ventricular workload without compromising systemic blood pressure.
- RF-Powered Efficiency: The use of advanced radio-frequency power transmission ensures a miniaturized footprint, making it suitable for a wide range of patient anatomies.
Validating the Clinical Roadmap
The #1 Medical Innovation award is not just a recognition of the device’s engineering, but a validation of the rigorous clinical data EnoPace has produced to date. During the TCT Shark Tank competition and subsequent technical sessions, the panel reviewed results from our latest clinical cohorts which showed:
- Sustained Hemodynamic Improvement: Patients experienced consistent heart rate reduction and improved cardiac output across the follow-up period.
- Reduction in Hospitalization: Preliminary data suggests a significant downward trend in heart failure-related hospital readmissions among treated patients.
- Safety and Biocompatibility: The procedure demonstrated a high safety profile with no device-related major adverse cardiac events (MACE) reported in the primary study group.
Strategic Implications for Global Healthcare
As heart failure affects over 15 million individuals across the US and Europe, the burden on healthcare systems is immense. The TCT award highlights the Harmony™ System as a cost-effective, scalable solution. By improving patient quality of life and reducing the frequency of intensive hospital stays, the technology provides a clear value proposition for both clinicians and healthcare administrators.
This recognition serves as a catalyst for our upcoming pivotal trials and our continued expansion into new global markets. We are currently scaling our manufacturing and distribution infrastructure—supported by 100% digital traceability—to ensure that this award-winning technology reaches the patients who need it most.
Moving Toward Commercialization
Winning the TCT #1 Medical Innovation award marks a turning point for EnoPace Biomedical. It transitions the Harmony™ System from a promising investigational concept into a validated clinical powerhouse. As we continue to work closely with global regulatory bodies, we remain committed to the evidence-based innovation that earned us this prestigious honor.
We extend our gratitude to our clinical partners, our dedicated engineering team, and the TCT committee for recognizing the transformative potential of the Harmony™ System.
